260 2030

Cited 6 times in

Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models

DC Field Value Language
dc.contributor.author윤혁준-
dc.contributor.author김희준-
dc.contributor.author장항석-
dc.contributor.author박정수-
dc.contributor.author장호진-
dc.contributor.author박기청-
dc.date.accessioned2021-02-15T07:51:51Z-
dc.date.available2021-02-15T07:51:51Z-
dc.date.issued2021-01-
dc.identifier.issn1661-6596-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/181661-
dc.description.abstractAnaplastic thyroid cancer (ATC) is an undifferentiated and advanced form of thyroid cancer, accompanied with a high ratio of epigenetic adjustment, which occurs more than genetic mutations. In this study, we aimed to evaluate the synergistic anticancer effect (in vitro and in vivo) of the new combination of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA) and sorafenib with radiation therapy in pre-clinical models of ATC. The ATC cell lines, YUMC-A1 and YUMC-A2, were isolated from the current patients who were treated with HNHA and sorafenib, either as monotherapy or combination therapy. Synergistic anticancer effect of the combination therapy on the intracellular signaling pathways and cell cycle was assessed via flow cytometry and immunoblot analysis. To examine tumor shrinkage activity in vivo, an ATC cell line-derived mouse xenograft model was used. Results showed that the combination therapy of HNHA and sorafenib with radiation promoted tumor suppression via caspase cleavage and cell cycle arrest in patient-derived ATC. In addition, the combination therapy of HNHA and sorafenib with radiation was more effective against ATC than therapy with HNHA or sorafenib with radiation. Thus, the combination of HNHA and sorafenib with radiation may be used as a novel curative approach for the treatment of ATC.-
dc.description.statementOfResponsibilityopen-
dc.languageINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES-
dc.publisherINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleSynergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorHyeok Jun Yun-
dc.contributor.googleauthorHee Jun Kim-
dc.contributor.googleauthorJungmin Kim-
dc.contributor.googleauthorSang Yong Kim-
dc.contributor.googleauthorHang-Seok Chang-
dc.contributor.googleauthorCheong Soo Park-
dc.contributor.googleauthorHo-Jin Chang-
dc.contributor.googleauthorKi Cheong Park-
dc.identifier.doi10.3390/ijms22020536-
dc.contributor.localIdA06022-
dc.contributor.localIdA05236-
dc.contributor.localIdA03488-
dc.contributor.localIdA01645-
dc.contributor.localIdA03496-
dc.contributor.localIdA01449-
dc.relation.journalcodeJ01133-
dc.identifier.eissn1422-0067-
dc.identifier.pmid33430361-
dc.subject.keywordN-hydroxy-7-(2-naphthylthio) heptanomide-
dc.subject.keywordapoptosis-
dc.subject.keywordpatient-derived anaplastic thyroid cancer-
dc.subject.keywordradiation therapy-
dc.subject.keywordsorafenib-
dc.contributor.alternativeNameYun, Hyeok Jun-
dc.contributor.affiliatedAuthor윤혁준-
dc.contributor.affiliatedAuthor김희준-
dc.contributor.affiliatedAuthor장항석-
dc.contributor.affiliatedAuthor박정수-
dc.contributor.affiliatedAuthor장호진-
dc.contributor.affiliatedAuthor박기청-
dc.citation.volume22-
dc.citation.number2-
dc.citation.startPage536-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, Vol.22(2) : 536, 2021-01-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.